JP2016505589A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505589A5
JP2016505589A5 JP2015548778A JP2015548778A JP2016505589A5 JP 2016505589 A5 JP2016505589 A5 JP 2016505589A5 JP 2015548778 A JP2015548778 A JP 2015548778A JP 2015548778 A JP2015548778 A JP 2015548778A JP 2016505589 A5 JP2016505589 A5 JP 2016505589A5
Authority
JP
Japan
Prior art keywords
seq
peptide
amino acids
composition
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548778A
Other languages
English (en)
Japanese (ja)
Other versions
JP6811014B2 (ja
JP2016505589A (ja
Filing date
Publication date
Priority claimed from GBGB1223386.2A external-priority patent/GB201223386D0/en
Application filed filed Critical
Publication of JP2016505589A publication Critical patent/JP2016505589A/ja
Publication of JP2016505589A5 publication Critical patent/JP2016505589A5/ja
Application granted granted Critical
Publication of JP6811014B2 publication Critical patent/JP6811014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548778A 2012-12-24 2013-12-20 B型肝炎ウイルスに対するワクチン Expired - Fee Related JP6811014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine
GB1223386.2 2012-12-24
PCT/GB2013/053410 WO2014102540A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189011A Division JP7187237B2 (ja) 2012-12-24 2018-10-04 B型肝炎ウイルスに対するワクチン

Publications (3)

Publication Number Publication Date
JP2016505589A JP2016505589A (ja) 2016-02-25
JP2016505589A5 true JP2016505589A5 (enExample) 2017-02-09
JP6811014B2 JP6811014B2 (ja) 2021-01-13

Family

ID=47682590

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015548778A Expired - Fee Related JP6811014B2 (ja) 2012-12-24 2013-12-20 B型肝炎ウイルスに対するワクチン
JP2018189011A Expired - Fee Related JP7187237B2 (ja) 2012-12-24 2018-10-04 B型肝炎ウイルスに対するワクチン
JP2021025254A Active JP7235785B2 (ja) 2012-12-24 2021-02-19 B型肝炎ウイルスに対するワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018189011A Expired - Fee Related JP7187237B2 (ja) 2012-12-24 2018-10-04 B型肝炎ウイルスに対するワクチン
JP2021025254A Active JP7235785B2 (ja) 2012-12-24 2021-02-19 B型肝炎ウイルスに対するワクチン

Country Status (12)

Country Link
US (3) US10300132B2 (enExample)
EP (2) EP3995146A1 (enExample)
JP (3) JP6811014B2 (enExample)
KR (3) KR102625645B1 (enExample)
CN (2) CN114028553A (enExample)
CA (1) CA2895459A1 (enExample)
DK (1) DK2935313T3 (enExample)
EA (1) EA201591213A1 (enExample)
ES (1) ES2906110T3 (enExample)
GB (1) GB201223386D0 (enExample)
PL (1) PL2935313T3 (enExample)
WO (1) WO2014102540A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
PT3463436T (pt) 2016-06-02 2023-12-28 Ultimovacs As Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
CA3085492A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
JP2021520414A (ja) * 2018-04-04 2021-08-19 アルティミューン インコーポレーティッド T細胞を誘発するワクチン組成物の組合せ及びその使用
CN113939527B (zh) * 2019-01-11 2025-10-28 新加坡科技研究局 Hla-a*11:01限制性乙型肝炎病毒(hbv)肽用于鉴别hbv特异性cd8+ t细胞的用途
CA3141238A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
BR112022003474A2 (pt) * 2019-08-29 2022-05-24 Triad Nat Security Llc Vacinas do vírus da hepatite b
EP4069271A1 (en) 2019-12-07 2022-10-12 ISA Pharmaceuticals B.V. Treatment of diseases related to hepatitis b virus
CN115335076B (zh) * 2020-01-09 2025-10-28 病毒治疗有限责任公司 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法
CA3184495A1 (en) * 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Anti-hbv antibodies and methods of use
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
WO2026093412A2 (en) * 2024-10-29 2026-05-07 Nec Oncoimmunity As Hbv vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
JP3566284B2 (ja) 1991-08-26 2004-09-15 ザ スクリップス リサーチ インスティテュート B型肝炎ウイルスに対する細胞障害性tリンパ球の応答を誘発するペプチド類
ATE227118T1 (de) * 1993-08-02 2002-11-15 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
CN1454082A (zh) 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Similar Documents

Publication Publication Date Title
Gottlieb et al. Epitope-based approaches to a universal influenza vaccine
Ma et al. Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response
Sun et al. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review
Fioravanti et al. Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology
Caballero et al. Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy
JP2016128513A5 (enExample)
EA201591213A1 (ru) Вакцины против вируса гепатита b
Li et al. Research progress of therapeutic vaccines for treating chronic hepatitis B
Kefalakes et al. Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable
JP6830955B2 (ja) 融合タンパク質
CN106421774B (zh) PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途
Zhang et al. Woodchuck hepatitis virus core antigen-based DNA and protein vaccines induce qualitatively different immune responses that affect T cell recall responses and antiviral effects
CN106317216B (zh) 一种促进h9n2禽流感疫苗免疫效果的活性肽及应用
JP2024534189A5 (enExample)
Wen et al. Vaccine therapies for chronic hepatitis B: can we go further?
Homs et al. HBV core region variability: effect of antiviral treatments on main epitopic regions
Jilkova et al. New Insights into Antibody-Mediated NK Cell Immunity in Hepatitis B: Editorial on" Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺ KLRC2⁻ CD16 hi subset linked to HBV outcomes"
WO2023138696A1 (zh) 有限化慢性乙肝的核苷(酸)类药物治疗的药物及方法
Madalinski Recent advances in hepatitis B vaccination.
Kim et al. Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model
Akbar et al. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical
Bar-Gal et al. Hepatitis B virus discovered in a Korean mummy dated to the 16th century: 927
CN108314708A (zh) 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用
Gaggar et al. Safety, Tolerability and Immunogenicity of GS-4774, an HBV-specific Therapeutic Vaccine, in Healthy Volunteers: 938
Makvandi et al. Study on Anti-Hepatitis B Surface Antibody Titer and Specific Interferon Gamma Response Among Dentists